cetirizine
Trade name: zyrtec
Approved
Dec 8, 1995
Cetirizine, a human metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via selective inhibition of peripheral H1 receptors. It is indicated for the relief of nasal and non-nasal symptoms associated with seasonal or perennial allergic rhinitis, hay fever and chronic idiopathic urticaria. Commonly reported adverse reactions of cetirizine include headache, dry mouth and drowsiness or fatigue. Pharmacokinetic interaction studies with Cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin. No interactions were observed. — NCATS
Clinical trial activity
94 trials · 79 clinical orgs · 52 marketing orgs
Earliest trial started Apr 1, 2000 (NCT00322907)
Timeline
1990s
- Dec 8, 1995
Earliest FDA Approval
- Dec 8, 1995
Johnson and Johnson — NDA Secondary Org
- Sep 27, 1996
Johnson and Johnson — First NDA Organization
- Sep 27, 1996
Johnson and Johnson — NDA Organization
2000s
- Jan 1, 2000
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2001
Earliest Phase 3 Sponsor(trial)
- Jan 1, 2002
- Nov 1, 2006
Ranbaxy — Marketing Organization
- Dec 27, 2007
Apotex — Marketing Organization
- Dec 27, 2007
Contract Pharmacal — Marketing Organization
- Dec 27, 2007
Mylan — Marketing Organization
- Dec 27, 2007
Perrigo — Marketing Organization
- Dec 27, 2007
PL Developments — Marketing Organization
- Dec 28, 2007
Glenmark Pharmaceuticals — Marketing Organization
- Dec 28, 2007
Actavis — Marketing Organization
- Dec 28, 2007
Wockhardt — Marketing Organization
- Dec 28, 2007
Heritage Pharma — Marketing Organization
- Jan 15, 2008
Dr. Reddy's Laboratories — Marketing Organization
- Feb 14, 2008
Sandoz — Marketing Organization
- Feb 14, 2008
Novartis — Marketing Organization
- Apr 22, 2008
Taro Pharmaceuticals — Marketing Organization
- Apr 22, 2008
Pharmaceutical Associates — Marketing Organization
- May 27, 2008
Teva — Marketing Organization
- Jun 17, 2008
Padagis Us — Marketing Organization
- Oct 6, 2008
Esteve Labs — Marketing Organization
- Oct 6, 2008
Bionpharma Inc — Marketing Organization
- Oct 10, 2008
Cypress Pharmaceutical — Marketing Organization
- Feb 19, 2009
Orbion Pharms — Marketing Organization
- Feb 19, 2009
Orchid Pharma — Marketing Organization
- Mar 30, 2009
Torrent Pharmaceuticals Limited — Marketing Organization
- Jun 26, 2009
Unichem — Marketing Organization
- Jul 23, 2009
Bionpharma Inc — NDA Secondary Org
- Aug 26, 2009
Unique Pharmaceuticals Ltd, India — Marketing Organization
- Aug 28, 2009
Atlantide Pharmaceuticals — Marketing Organization
- Sep 25, 2009
Lannett Company, Inc. — Marketing Organization
- Oct 7, 2009
Amneal Pharmaceuticals — Marketing Organization
- Nov 12, 2009
Saptalis Pharmaceuticals — Marketing Organization
- Nov 12, 2009
Micro Labs Ltd India — Marketing Organization
- Nov 12, 2009
Department of Veteran Affairs — Marketing Organization
2010s
- Feb 2, 2010
Aurobindo Pharma — Marketing Organization
- Jun 15, 2010
Marksans Pharma — Marketing Organization
- Apr 22, 2011
Chartwell Pharmaceuticals — Marketing Organization
- Aug 30, 2011
Sun Pharmaceuticals — Marketing Organization
- Oct 17, 2011
Apnar Pharma — Marketing Organization
- Oct 17, 2011
Athem — Marketing Organization
- Nov 16, 2012
Tris Pharma, Inc. — Marketing Organization
- Jul 25, 2013
Cipla — Marketing Organization
- Mar 11, 2014
IPCA Laboratories Ltd. — Marketing Organization
- Feb 19, 2015
Jubilant Innovation Ltd. — Marketing Organization
- Mar 8, 2016
Novel Anti-Infective Technologies, LLC — Marketing Organization
- May 30, 2017
Eyevance — NDA Secondary Org
- Jul 21, 2017
Strides Pharma Science — Marketing Organization
- Dec 22, 2017
Granules India — Marketing Organization
- Mar 13, 2019
Hetero Labs Ltd — Marketing Organization
- May 16, 2019
Quagen Pharma — Marketing Organization
- Oct 4, 2019
JDP Therapeutics, Inc. — Marketing Organization
- Oct 4, 2019
Jdp — Marketing Organization
- Oct 4, 2019
Jdp — NDA Secondary Org
2020s
- Sep 21, 2020
Catalent — Marketing Organization
- Sep 21, 2020
Micron Technologies — Marketing Organization
Indications
Approved for
Studied for
- Alopecia · Phase 4
- Altitude Sickness · Phase 4
- Asthma · Phase 4
- Body Fat Distribution · Phase 1/Phase 2
- Breast Neoplasms · Phase 3
- Burns · Phase 1/Phase 2
- Chronic Urticaria · Phase 2
- Conjunctivitis, Allergic · Phase 2
- COVID-19 · Phase 4
- Dermatitis · Phase 3
- Dermatitis, Atopic · Phase 3
- Diabetes Mellitus, Type 2 · Phase 4
- Diabetic Neuropathies · Phase 4
- Eczema · Phase 3
- Endometrial Neoplasms · Phase 3
- Esophageal Neoplasms · Phase 3
- Essential Hypertension · Phase 3
- Exercise · Phase 4
- Head and Neck Neoplasms · Phase 3
- Healthy Volunteers · Phase 1
- Hypersensitivity · Phase 4
- Hypertension · Phase 1
- Lung Neoplasms · Phase 3
- Malaria · Phase 2
- Migraine Disorders · Phase 1
- Multiple Sclerosis · Phase 4
- Multiple Sclerosis, Relapsing-Remitting · Phase 4
- Neoplasms · Phase 2
- Neuralgia · Phase 4
- Neuromyelitis Optica · Phase 1/Phase 2
- Otitis Media with Effusion · Phase 4
- Ovarian Neoplasms · Phase 3
- Pemphigus · Phase 3
- Prostatitis · Early Phase 1
- Pruritus · Phase 4
- Rhinitis, Allergic · Phase 4
- Rhinitis, Allergic, Perennial · Phase 4
- Rhinitis, Allergic, Seasonal · Phase 4
- Ureteral Diseases · Phase 3
- Urticaria · Phase 4
- Uterine Cervical Neoplasms · Phase 3
Mechanism of action
- Histamine H1 receptorANTAGONIST
HRH1 antagonist
Combination products
zyrtec-d 12 hour
with pseudoephedrine
Approval history
- approvedDec 8, 1995
Chemistry & pharmacology
SMILES
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1- Mol. weight
- 388.9 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral, Topical
- Availability
- Over the Counter
Oral
Yes
Parenteral
Yes
Topical
Yes
Sources
- ChEMBLCHEMBL1000 ↗
- WikipediaCotrifazid ↗
- NCATSYO7261ME24 ↗
- ChEMBLCHEMBL1607273 ↗
- ChEMBLCHEMBL1201113 ↗
- WikipediaCetirizine ↗
Also known as
- allacan
- allertek
- becoallergy
- cetec
- ceterizine
- cetirizin
- cetirizin
- cetirizina
- cetirizina
- cetirizine
- cetirizine
- cetirizine
- cetirizine
- cetirizine
- cetirizine
- cetirizine
- cetirizine
- cetirizine
- cetirizine
- cetirizine di hcl
- cetirizine dihydrochloride
- cetirizine hcl
- cetirizine hcl
- cetirizine hcl
- cetirizine hydrochloride
- cetirizine hydrochloride
- cetirizine hydrochloride
- cetirizine hydrochloride
- cetirizine hydrochloride
- cetirizinum
- cetirizinum
- cetirocol
- cotrifazid
- cotrifazid
- p-071
- p-071
- piriteze
- pollenshield
- ziralton
- zirtek
- zirtek
- zynor
- zyrtec
- zyrtec
- zyrtec
- zyrtec
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07236372 | N/A | Nov 30, 2025 | University of Phayao |
| NCT06890260 | N/A | Apr 11, 2025 | Zhejiang University |
| NCT06819774 | Phase 3 | Apr 22, 2024 | Shandong New Time Pharmaceutical Co., LTD |
| NCT05946551 | Phase 3 | Jan 31, 2024 | Emory University |
| NCT06126991 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2023 | Jiao Tong University |
| NCT06121518 | Phase 3 | Jul 31, 2023 | Chong Kun Dang Pharmaceutical, Hanyang University |
| NCT05931224 | Phase 3 | Jun 28, 2023 | Chong Kun Dang Pharmaceutical, Seoul National University |
| NCT05526703 | Phase 3 | Sep 28, 2022 | Chong Kun Dang Pharmaceutical |
| NCT05476679 | Phase 1/Phase 2 (Phase 2) | Sep 25, 2022 | Raziel Therapeutics Ltd. |
| NCT05540912 | Phase 1 | Sep 15, 2022 | Chong Kun Dang Pharmaceutical |
| NCT04836806 | Phase 4 | Aug 31, 2021 | Emory University |
| NCT05095311 | Phase 4 | May 19, 2021 | Indiana University |
| NCT06754410 | Phase 3 | Mar 1, 2021 | South Valley University |
| NCT04293822 | Phase 4 | Jun 30, 2020 | Assiut University |
| NCT04237090 | Phase 3 | Feb 29, 2020 | Ciusss de L'Est de l'Île de Montréal |
| NCT04189588 | Phase 2 | Feb 29, 2020 | JDP Therapeutics, Inc., Tersera Theraps Llc |
| NCT04481412 | Phase 2/Phase 3 (Phase 3) | Feb 16, 2020 | Cairo University |
| NCT04071821 | Phase 1 | Oct 1, 2019 | Frontage Laboratories, Inc., Seattle Gummy Company |
| NCT03772158 | Phase 1 | Dec 11, 2018 | Algorithme Pharma Inc, Johnson and Johnson |
| NCT03590912 | Phase 4 | Aug 31, 2018 | Lumbini Medical College |
Organizations
Research & Development (79)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 12 | 11 | 5 | 2005 |
| Merck | For profit | 10 | 10 | 2 | 2001 |
| Chong Kun Dang Pharmaceutical | For profit | 4 | 4 | 2 | 2022 |
| JDP Therapeutics, Inc. | For profit | 4 | 4 | 3 | 2011 |
| Faes Farma, S.A. | For profit | 3 | 3 | 2 | 2004 |
| Genzyme | For profit | 3 | 3 | 3 | 2014 |
| Johnson and Johnson | For profit | 3 | 3 | 2 | 2001 |
| Medical University of Lodz | Academic/Hospital | 3 | 1 | 2 | 2004 |
| Sanofi | For profit | 3 | 0 | 3 | 2014 |
| AAIPharma | For profit | 2 | 0 | 1 | 2006 |
| Actavis | For profit | 2 | 2 | 1 | 2006 |
| Algorithme Pharma Inc | For profit | 2 | 0 | 1 | 2011 |
| Dr. Reddy's Laboratories | For profit | 2 | 2 | 1 | 2006 |
| Emory University | Academic/Hospital | 2 | 2 | 2 | 2021 |
| Hoosier Cancer Research Network | Academic/Hospital | 2 | 2 | 1 | 2002 |
| Indiana University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Lambda Therapeutic Research Ltd | For profit | 2 | 0 | 1 | 2006 |
| McNeil | For profit | 2 | 1 | 2 | 2011 |
| Mylan | For profit | 2 | 2 | 1 | 2002 |
| Novum Pharmaceutical Research Services | For profit | 2 | 0 | 1 | 2002 |
Marketing (70)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Actavis | For profit | MKTG | Dec 28, 2007 |
| Actavis | For profit | SYN | May 9, 2008 |
| Amneal Pharmaceuticals | For profit | MKTG | Oct 7, 2009 |
| Amneal Pharmaceuticals | For profit | SYN | Jan 21, 2010 |
| Apnar Pharma | For profit | MKTG | Oct 17, 2011 |
| Apotex | For profit | SYN | Aug 12, 2016 |
| Apotex | For profit | MKTG | Dec 27, 2007 |
| Athem | For profit | MKTG | Oct 17, 2011 |
| Atlantide Pharmaceuticals | For profit | MKTG | Aug 28, 2009 |
| Aurobindo Pharma | For profit | MKTG | Feb 2, 2010 |
| Aurobindo Pharma | For profit | SYN | Dec 16, 2009 |
| Bionpharma Inc | For profit | NDA2 | Jul 23, 2009 |
| Bionpharma Inc | For profit | MKTG | Oct 6, 2008 |
| Catalent | For profit | MKTG | Sep 21, 2020 |
| Chartwell Pharmaceuticals | For profit | MKTG | Apr 22, 2011 |
| Chartwell Pharmaceuticals | For profit | SYN | May 9, 2008 |
| Cipla | For profit | MKTG | Jul 25, 2013 |
| Contract Pharmacal | For profit | MKTG | Dec 27, 2007 |
| Cypress Pharmaceutical | For profit | MKTG | Oct 10, 2008 |
| Department of Veteran Affairs | Government | MKTG | Nov 12, 2009 |
| Dr. Reddy's Laboratories | For profit | MKTG | Jan 15, 2008 |
| Esteve Labs | For profit | MKTG | Oct 6, 2008 |
| Esteve Labs | For profit | SYN | Oct 6, 2008 |
| Eyevance | For profit | NDA2 | May 30, 2017 |
| Glenmark Pharmaceuticals | For profit | MKTG | Dec 28, 2007 |
| Granules India | For profit | SYN | Dec 22, 2017 |
| Granules India | For profit | MKTG | Dec 22, 2017 |
| Heritage Pharma | For profit | MKTG | Dec 28, 2007 |
| Hetero Labs Ltd | For profit | MKTG | Mar 13, 2019 |
| IPCA Laboratories Ltd. | For profit | MKTG | Mar 11, 2014 |
| JDP Therapeutics, Inc. | For profit | MKTG | Oct 4, 2019 |
| Jdp | For profit | MKTG | Oct 4, 2019 |
| Jdp | For profit | NDA2 | Oct 4, 2019 |
| Johnson and Johnson | For profit | NDA | Sep 27, 1996 |
| Johnson and Johnson | For profit | NDA2 | Dec 8, 1995 |
| Jubilant Innovation Ltd. | For profit | MKTG | Feb 19, 2015 |
| Lannett Company, Inc. | For profit | MKTG | Sep 25, 2009 |
| Marksans Pharma | For profit | MKTG | Jun 15, 2010 |
| Micro Labs Ltd India | For profit | MKTG | Nov 12, 2009 |
| Micron Technologies | For profit | MKTG | Sep 21, 2020 |
| Mylan | For profit | MKTG | Dec 27, 2007 |
| Mylan | For profit | SYN | Nov 12, 2009 |
| Novartis | For profit | MKTG | Feb 14, 2008 |
| Novel Anti-Infective Technologies, LLC | For profit | MKTG | Mar 8, 2016 |
| Orbion Pharms | For profit | MKTG | Feb 19, 2009 |
| Orchid Pharma | For profit | MKTG | Feb 19, 2009 |
| PL Developments | For profit | MKTG | Dec 27, 2007 |
| Padagis Us | For profit | MKTG | Jun 17, 2008 |
| Perrigo | For profit | MKTG | Dec 27, 2007 |
| Perrigo | For profit | SYN | Jun 17, 2008 |
| Pharmaceutical Associates | For profit | MKTG | Apr 22, 2008 |
| Quagen Pharma | For profit | MKTG | May 16, 2019 |
| Ranbaxy | For profit | MKTG | Nov 1, 2006 |
| Sandoz | For profit | MKTG | Feb 14, 2008 |
| Saptalis Pharmaceuticals | For profit | MKTG | Nov 12, 2009 |
| Strides Pharma Science | For profit | MKTG | Jul 21, 2017 |
| Sun Pharmaceuticals | For profit | SYN | Aug 30, 2011 |
| Sun Pharmaceuticals | For profit | MKTG | Aug 30, 2011 |
| Sun Pharmaceuticals | For profit | SYN | Dec 27, 2007 |
| Sun Pharmaceuticals | For profit | SYN | Dec 27, 2007 |
| Taro Pharmaceuticals | For profit | MKTG | Apr 22, 2008 |
| Teva | For profit | SYN | Feb 25, 2008 |
| Teva | For profit | MKTG | May 27, 2008 |
| Torrent Pharmaceuticals Limited | For profit | MKTG | Mar 30, 2009 |
| Torrent Pharmaceuticals Limited | For profit | SYN | Apr 15, 2010 |
| Tris Pharma, Inc. | For profit | MKTG | Nov 16, 2012 |
| Unichem | For profit | MKTG | Jun 26, 2009 |
| Unique Pharmaceuticals Ltd, India | For profit | MKTG | Aug 26, 2009 |
| Unique Pharmaceuticals Ltd, India | For profit | SYN | Aug 26, 2009 |
| Wockhardt | For profit | MKTG | Dec 28, 2007 |